Cargando…

P1000: JUVENILE MYELOMONOCYTIC LEUKEMIA (JMML) INHIBITS T CELL PROLIFERATION VIA THE ECTONUCLEOTIDASE CD39 AND THE PURINERGIC NETWORK

Detalles Bibliográficos
Autores principales:	Rajak, Jovana, Koleci, Naile, Mesesan, Andreea, Flotho, Christian, Niemeyer, Charlotte, Bengsch, Bertram, Erlacher, Miriam
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10431500/ http://dx.doi.org/10.1097/01.HS9.0000970904.58843.2d

Ejemplares similares

Current Treatment of Juvenile Myelomonocytic Leukemia
por: Mayerhofer, Christina, et al.
Publicado: (2021)

MicroRNA fingerprints in juvenile myelomonocytic leukemia (JMML) identified miR-150-5p as a tumor suppressor and potential target for treatment
por: Leoncini, Pier Paolo, et al.
Publicado: (2016)

Long non-coding RNAs as novel therapeutic targets in juvenile myelomonocytic leukemia
por: Hofmans, Mattias, et al.
Publicado: (2021)

CREBBP is a target of epigenetic, but not genetic, modification in juvenile myelomonocytic leukemia
por: Fluhr, Silvia, et al.
Publicado: (2016)

Induced Pluripotent Stem Cells to Model Juvenile Myelomonocytic Leukemia: New Perspectives for Preclinical Research
por: Wehbe, Zeinab, et al.
Publicado: (2021)

S206: ONCO-FETAL REPROGRAMMING DRIVES HIGH-RISK JUVENILE MYELOMONOCYTIC LEUKEMIA, WHICH CAN BE TARGETED BY ANTI-CD52 TREATMENT
por: Hartmann, Mark, et al.
Publicado: (2023)

Stem cell origins of JMML
por: Sundaravel, Sriram, et al.
Publicado: (2021)

Germline CBL mutations cause developmental abnormalities and predispose to juvenile myelomonocytic leukemia
por: Niemeyer, Charlotte M., et al.
Publicado: (2010)

CircRNAs Dysregulated in Juvenile Myelomonocytic Leukemia: CircMCTP1 Stands Out
por: Dal Molin, Anna, et al.
Publicado: (2021)

Epigenetic Profiling of PTPN11 Mutant JMML Hematopoietic Stem and Progenitor Cells Reveals an Aberrant Histone Landscape
por: Sinha, Roshani, et al.
Publicado: (2023)

Monitoring and characterizing soluble and membrane-bound ectonucleotidases CD73 and CD39
por: Goueli, Said A., et al.
Publicado: (2019)

Ectonucleotidase CD39 is highly expressed on ATLL cells and is responsible for their immunosuppressive function
por: Nagate, Yasuhiro, et al.
Publicado: (2020)

The ectonucleotidases CD39 and CD73 on T cells: The new pillar of hematological malignancy
por: Jiang, Xuan, et al.
Publicado: (2023)

Genome-wide DNA methylation is predictive of outcome in juvenile myelomonocytic leukemia
por: Stieglitz, Elliot, et al.
Publicado: (2017)

Second allogeneic stem cell transplantation can rescue a significant proportion of patients with JMML relapsing after first allograft
por: Vinci, Luca, et al.
Publicado: (2023)

The Role of Ectonucleotidases CD39 and CD73 and Adenosine Signaling in Solid Organ Transplantation
por: Roberts, Veena, et al.
Publicado: (2014)

NTPDase1/CD39 Ectonucleotidase Is Necessary for Normal Arterial Diameter Adaptation to Flow
por: Favre, Julie, et al.
Publicado: (2023)

Determination of Ras-GTP and Ras-GDP in patients with acute myelogenous leukemia (AML), myeloproliferative syndrome (MPS), juvenile myelomonocytic leukemia (JMML), acute lymphocytic leukemia (ALL), and malignant lymphoma: assessment of mutational and indirect activation
por: Raepple, D., et al.
Publicado: (2008)

T Lymphocyte Inhibition by Tumor-Infiltrating Dendritic Cells Involves Ectonucleotidase CD39 but Not Arginase-1
por: Trad, Malika, et al.
Publicado: (2015)

Proteomic Analysis of an Induced Pluripotent Stem Cell Model Reveals Strategies to Treat Juvenile Myelomonocytic Leukemia
por: Pearson, Stella, et al.
Publicado: (2019)

RAS-pathway mutation patterns define epigenetic subclasses in juvenile myelomonocytic leukemia
por: Lipka, Daniel B., et al.
Publicado: (2017)

Nucleotide Analog ARL67156 as a Lead Structure for the Development of CD39 and Dual CD39/CD73 Ectonucleotidase Inhibitors
por: Schäkel, Laura, et al.
Publicado: (2020)

The Genomic Landscape of Juvenile Myelomonocytic Leukemia
por: Stieglitz, Elliot, et al.
Publicado: (2015)

Ectonucleotidases in Cancer and Inflammation
por: Stagg, John, et al.
Publicado: (2012)

The ectonucleotidase ENTPD1/CD39 limits biliary injury and fibrosis in mouse models of sclerosing cholangitis
por: Peng, Zhen‐Wei, et al.
Publicado: (2017)

Protein kinase inhibitor ceritinib blocks ectonucleotidase CD39 – a promising target for cancer immunotherapy
por: Schäkel, Laura, et al.
Publicado: (2022)

Molecular Targets for the Treatment of Juvenile Myelomonocytic Leukemia
por: Liu, Xiaoling, et al.
Publicado: (2012)

Genomic and Epigenomic Landscape of Juvenile Myelomonocytic Leukemia
por: Fiñana, Claudia, et al.
Publicado: (2022)

Resident Cardiac Immune Cells and Expression of the Ectonucleotidase Enzymes CD39 and CD73 after Ischemic Injury
por: Bönner, Florian, et al.
Publicado: (2012)

The Role of Cluster of Differentiation 39 (CD39) and Purinergic Signaling Pathway in Viral Infections
por: Elsaghir, Alaa, et al.
Publicado: (2023)

Ectonucleotidases in Intestinal and Hepatic Inflammation
por: Vuerich, Marta, et al.
Publicado: (2019)

Ectonucleotidases in Acute and Chronic Inflammation
por: Giuliani, Anna Lisa, et al.
Publicado: (2021)

Sulfated Polysaccharides from Macroalgae Are Potent Dual Inhibitors of Human ATP-Hydrolyzing Ectonucleotidases NPP1 and CD39
por: Lopez, Vittoria, et al.
Publicado: (2021)

Relationship between the Gene Expression of Adenosine Kinase Isoforms and the Expression of CD39 and CD73 Ectonucleotidases in Colorectal Cancer
por: Zhulai, G. A., et al.
Publicado: (2023)

Novel splicing-factor mutations in juvenile myelomonocytic leukemia
por: Takita, J, et al.
Publicado: (2012)

Molecular and phenotypic diversity of CBLmutated juvenile myelomonocytic leukemia
por: Hecht, Anna, et al.
Publicado: (2020)

P1072: NATURAL HISTORY OF JUVENILE MYELOMONOCYTIC LEUKEMIA
por: Yang, W., et al.
Publicado: (2022)

Single-Center Experience With Epigenetic Treatment for Juvenile Myelomonocytic Leukemia
por: Marcu, Andra, et al.
Publicado: (2020)

Heterogeneous disease-propagating stem cells in juvenile myelomonocytic leukemia
por: Louka, Eleni, et al.
Publicado: (2021)

Clinical and molecular features of CBL-mutated juvenile myelomonocytic leukemia
por: Yoshida, Taro, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_27jcta488f55nkku0gq29f8v7t